Zobrazeno 1 - 10 of 1 354 pro vyhledávání: '"ibritumomab tiuxetan"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma
Autor: Ollila TA, Olszewski AJ
Publikováno v: Cancer Management and Research, Vol Volume 13, Pp 3935-3952 (2021)
Thomas A Ollila,1,2 Adam J Olszewski1,2 1Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA; 2Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USACorrespondence: Adam J OlszewskiDepartment of
Externí odkaz: https://doaj.org/article/6439d6433f4d4796b75f19f9930b5f52
Zobrazit plný text záznamu
3
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Autor: Lopez-Guillermo, Armando, Canales, Miguel Angel, Dlouhy, Ivan, Mercadal, Santiago, Briones, Javier, Martin Garcia-Sancho, Alejandro, Sancho, Juan Manuel, Maria Moraleda, Jose, Terol, Maria Jose, Salar, Antonio, Palomera, Luis, Gardella, Santiago, Jarque, Isidro, Ferrer, Secundino, Bargay, Joan, Lopez, Andres, Panizo, Carlos, Muntañola, Anna, Montalban, Carlos, Conde, Eulogio, Hernandez, Miguel T., Soler, Alfons, Garcia Marco, Jose A., Deben, Guillermo, Marin, Julian, Tomas, Jose Francisco
Publikováno v: LEUKEMIA & LYMPHOMA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Leukemia & lymphoma
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b64a3d520daac0111273a2996543fd52
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10714
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
The standardized uptake value calculated from 111In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by 90Y- ibritumomab tiuxetan therapy
Autor: Kume, Ayaka, Toriihara, Akira, Shimizu, Ryo, Harata, Naoki, Isogai, Jun, Tanaka, Hiroaki
Publikováno v: Journal of Clinical and Experimental Hematopathology : JCEH
90Y-Ibritumomab tiuxetan (IT) therapy is a radioimmunotherapy for indolent B-cell lymphoma. Several predictors of insufficient therapeutic effects have been reported. We performed a retrospective study at a single institute to investigate whether 111
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0dc07f11fa39017be18b7a0122b2d3f8
http://europepmc.org/articles/PMC8053570
Zobrazit plný text záznamu
7
The standardized uptake value calculated from 111In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by 90Y- ibritumomab tiuxetan therapy
Autor: Ayaka Kume, Akira Toriihara, Naoki Harata, Ryo Shimizu, Hiroaki Tanaka, Jun Isogai
Publikováno v: Journal of Clinical and Experimental Hematopathology. 61:29-34
90Y-Ibritumomab tiuxetan (IT) therapy is a radioimmunotherapy for indolent B-cell lymphoma. Several predictors of insufficient therapeutic effects have been reported. We performed a retrospective study at a single institute to investigate whether 111
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d72cc212481e48a304b46b97ea34ebcb
https://doi.org/10.3960/jslrt.20055
Zobrazit plný text záznamu
8
Consolidation with 90 Yttrium‐ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma
Autor: Isao Yoshida, Katsuhiro Miura, Akiyo Yoshida, Ilseung Choi, Tadashi Yoshino, Jun Takizawa, Hideo Yagi, Yoshihiro Hatta, Shinobu Tamura, Masaki Iino, Koichi Kitazume, Kazuhiko Yamamoto, Yasufumi Masaki, Shigeo Nakamura, Taro Masunari, Ritsuro Suzuki, Masatoshi Kanno, Yoshinobu Maeda, Yasutaka Kakinoki, Hideki Tsujimura, Takashi Yoshida
Publikováno v: Hematological Oncology. 39:51-59
Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48fcb0ea06b56a5915415508f5771d57
https://doi.org/10.1002/hon.2809
Zobrazit plný text záznamu
9
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma
Autor: Erin Taylor, Felipe Samaniego, Loretta J. Nastoupil, Lei Feng, Sattva S. Neelapu, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Nathan Fowler, Maria Alma Rodriguez, Michelle A. Fanale
Publikováno v: Leukemia & Lymphoma. 62:58-67
R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25fb5521254743744243835b63144383
https://doi.org/10.1080/10428194.2020.1821005
Zobrazit plný text záznamu
10
Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma
Autor: Joseph D. Rosenblatt, Izidore S. Lossos, Isildinha M. Reis, Juan Pablo Alderuccio
Publikováno v: Leukemia & Lymphoma. 61:3234-3238
The best upfront therapy for patients with non-gastric extranodal marginal zone lymphoma (EMZL) remains unclear. Patients with localized disease are usually treated with radiation therapy resulting...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c8f391c52bfdb284457d8c9c60297ee
https://doi.org/10.1080/10428194.2020.1802449
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje